Literature DB >> 30003898

Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.

Grzegorz Kijanka1, Jared S Bee2, Samuel A Korman2, Yuling Wu3, Lorin K Roskos3, Mark A Schenerman2, Bram Slütter1, Wim Jiskoot4.   

Abstract

Protein aggregates are one of the several risk factors for undesired immunogenicity of biopharmaceuticals. However, it remains unclear which features determine whether aggregates will trigger an unwanted immune response. The aim of this study was to determine the effect of aggregates' size on their relative immunogenicity. A monoclonal murine IgG1 was stressed by exposure to low pH and elevated temperature followed by stirring to obtain aggregates widely differing in size. Aggregate fractions enriched in soluble oligomers, submicron size particles and micron size particles were isolated via centrifugation or size-exclusion chromatography and characterized physicochemically. The secondary and tertiary structures of aggregates were altered in a similar way for all the fractions, while no substantial chemical degradation was observed. Development of anti-drug antibodies was measured after subcutaneous administration of each enriched fraction to BALB/c mice. Among all tested fractions, the most immunogenic was the one highly enriched in submicron size particles (∼100-1000 nm). Fractions composed of micron size (>1-100 μm) particles or soluble oligomers (<100 nm) were not immunogenic under the dosing regimen studied in this work. These results show that aggregate size is an important factor for protein immunogenicity.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  immunogenicity; microparticle(s); monoclonal antibody(s); nanoparticle(s); particle size; protein aggregation

Mesh:

Substances:

Year:  2018        PMID: 30003898     DOI: 10.1016/j.xphs.2018.06.029

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.

Authors:  Nils Krause; Sebastian Kuhn; Erik Frotscher; Felix Nikels; Andrea Hawe; Patrick Garidel; Tim Menzen
Journal:  AAPS J       Date:  2021-01-04       Impact factor: 4.009

Review 2.  Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.

Authors:  Myriam Nabhan; Marc Pallardy; Isabelle Turbica
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 3.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Nicole L Jarvi; Sathy V Balu-Iyer
Journal:  BioDrugs       Date:  2021-02-01       Impact factor: 5.807

Review 4.  Development of vaccine formulations: past, present, and future.

Authors:  Carmine D'Amico; Flavia Fontana; Ruoyu Cheng; Hélder A Santos
Journal:  Drug Deliv Transl Res       Date:  2021-02-17       Impact factor: 4.617

5.  Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Authors:  Michael D Swanson; Shantel Rios; Sarita Mittal; George Soder; Vibha Jawa
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

Review 6.  Protein aggregation and immunogenicity of biotherapeutics.

Authors:  Ngoc B Pham; Wilson S Meng
Journal:  Int J Pharm       Date:  2020-06-09       Impact factor: 5.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.